BioCentury | Apr 20, 2018
Company News

UCB buys rights to seizure candidate

...sodium channels and modulates collapsin response mediator protein-2 (DPYSL2; CRMP-2). Elizabeth S. Eaton USL261, iti-111, Intranasal midazolam Proximagen UCB S.A. Upsher-Smith...
BioCentury | Jun 16, 2016
Translation in Brief

Dysfunction junction

...generic analgesic with secondary gap junction-inhibiting activity. Tonabersat is a neuronal gap junction blocker that Upsher-Smith Laboratories Inc....
BioCentury | May 23, 2016
Clinical News

USL311: Phase I/II started

...solid tumors and the Phase II portion will enroll patients with relapsed or recurrent GBM. Upsher-Smith Laboratories Inc....
BioCentury | Feb 8, 2016
Company News

Saniona, Upsher-Smith deal

...eligible for $30 million in undisclosed preclinical, clinical and regulatory milestones, plus undisclosed tiered royalties. Upsher-Smith...
...or financial terms, and Saniona did not respond to inquiries. Saniona AB (AktieTorget:SANION), Ballerup, Denmark Upsher-Smith Laboratories Inc....
BioCentury | Jan 4, 2016
Company News

Upsher-Smith, Roche deal

...regulatory and sales milestones, plus undisclosed tiered royalties. The companies did not respond to inquiries. Upsher-Smith Laboratories Inc....
BioCentury | Jun 8, 2015
Clinical News

Qudexy XR topiramate regulatory update

...FDA approved an sNDA from Upsher-Smith for Qudexy XR topiramate as initial monotherapy for partial-onset seizures...
...extended-release formulation of topiramate, a sodium channel blocker, GABA receptor agonist and AMPA receptor antagonist. Upsher-Smith Laboratories Inc....
BioCentury | Dec 8, 2014
Company News

Upsher-Smith, MRC deal

...an independent life science technology transfer charity. Financial terms of the deal are not disclosed. Upsher-Smith Laboratories Inc....
BioCentury | Sep 22, 2014
Strategy

Weighing in on obesity

...LLC/ Ipsen Group (Euronext:IPN; Pink:IPSEY) RM-493 Small peptide melanocortin 4 receptor (MC4R) agonist Ph II Upsher-Smith Laboratories Inc....
BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

...ü Vimovo naproxen/esomeprazole Horizon Pharma Inc. (NASDAQ:HZNP) OA, RA and ankylosing spondylitis ü Vogelxo testosterone Upsher-Smith Laboratories Inc....
...Topical testosterone products Testosterone 1% (B) Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL)/Prasco Laboratories/Upsher-Smith Laboratories Inc. ü Vogelxo testosterone 1% Upsher-Smith Laboratories Inc....
BioCentury | Jul 21, 2014
Company News

Upsher-Smith sales and marketing update

...extended-release formulation of topiramate, a sodium channel blocker, GABA receptor agonist and AMPA receptor antagonist. Upsher-Smith Laboratories Inc....
Items per page:
1 - 10 of 85
BioCentury | Apr 20, 2018
Company News

UCB buys rights to seizure candidate

...sodium channels and modulates collapsin response mediator protein-2 (DPYSL2; CRMP-2). Elizabeth S. Eaton USL261, iti-111, Intranasal midazolam Proximagen UCB S.A. Upsher-Smith...
BioCentury | Jun 16, 2016
Translation in Brief

Dysfunction junction

...generic analgesic with secondary gap junction-inhibiting activity. Tonabersat is a neuronal gap junction blocker that Upsher-Smith Laboratories Inc....
BioCentury | May 23, 2016
Clinical News

USL311: Phase I/II started

...solid tumors and the Phase II portion will enroll patients with relapsed or recurrent GBM. Upsher-Smith Laboratories Inc....
BioCentury | Feb 8, 2016
Company News

Saniona, Upsher-Smith deal

...eligible for $30 million in undisclosed preclinical, clinical and regulatory milestones, plus undisclosed tiered royalties. Upsher-Smith...
...or financial terms, and Saniona did not respond to inquiries. Saniona AB (AktieTorget:SANION), Ballerup, Denmark Upsher-Smith Laboratories Inc....
BioCentury | Jan 4, 2016
Company News

Upsher-Smith, Roche deal

...regulatory and sales milestones, plus undisclosed tiered royalties. The companies did not respond to inquiries. Upsher-Smith Laboratories Inc....
BioCentury | Jun 8, 2015
Clinical News

Qudexy XR topiramate regulatory update

...FDA approved an sNDA from Upsher-Smith for Qudexy XR topiramate as initial monotherapy for partial-onset seizures...
...extended-release formulation of topiramate, a sodium channel blocker, GABA receptor agonist and AMPA receptor antagonist. Upsher-Smith Laboratories Inc....
BioCentury | Dec 8, 2014
Company News

Upsher-Smith, MRC deal

...an independent life science technology transfer charity. Financial terms of the deal are not disclosed. Upsher-Smith Laboratories Inc....
BioCentury | Sep 22, 2014
Strategy

Weighing in on obesity

...LLC/ Ipsen Group (Euronext:IPN; Pink:IPSEY) RM-493 Small peptide melanocortin 4 receptor (MC4R) agonist Ph II Upsher-Smith Laboratories Inc....
BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

...ü Vimovo naproxen/esomeprazole Horizon Pharma Inc. (NASDAQ:HZNP) OA, RA and ankylosing spondylitis ü Vogelxo testosterone Upsher-Smith Laboratories Inc....
...Topical testosterone products Testosterone 1% (B) Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL)/Prasco Laboratories/Upsher-Smith Laboratories Inc. ü Vogelxo testosterone 1% Upsher-Smith Laboratories Inc....
BioCentury | Jul 21, 2014
Company News

Upsher-Smith sales and marketing update

...extended-release formulation of topiramate, a sodium channel blocker, GABA receptor agonist and AMPA receptor antagonist. Upsher-Smith Laboratories Inc....
Items per page:
1 - 10 of 85